J. B. O'connell, M. A. Maggard, and C. Y. Ko, Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging, JNCI J Natl Cancer Inst, vol.96, pp.1420-1425, 2004.

E. Van-cutsem, A. Cervantes, R. Adam, A. Sobrero, H. J. Van-krieken et al., ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, vol.27, issue.8, pp.1386-422, 2016.

R. L. Siegel, K. D. Miller, S. A. Fedewa, D. J. Ahnen, R. Meester et al., Colorectal cancer statistics, CA Cancer J Clin, vol.67, issue.3, pp.177-93, 2017.

M. J. Overman, J. Modak, S. Kopetz, R. Murthy, J. C. Yao et al., Use of research biopsies in clinical trials: are risks and benefits adequately discussed?, J Clin Oncol, vol.31, issue.1, pp.17-22, 2013.

A. Lièvre, P. Artru, M. Guiu, P. Laurent-puig, J. L. Merlin et al., The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011, Eur J Cancer, vol.49, issue.9, pp.2126-2159, 2013.

A. Chan, R. Chiu, and Y. Lo, Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis, Ann Clin Biochem, vol.40, issue.2, pp.122-152, 2003.

S. A. Leon, B. Shapiro, D. M. Sklaroff, and M. J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977.

H. Schwarzenbach, D. Hoon, and K. Pantel, Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, vol.11, issue.6, pp.426-463, 2011.

T. Lecomte, A. Berger, F. Zinzindohoué, S. Micard, B. Landi et al., Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, vol.100, issue.5, pp.542-550, 2002.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, D. L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

A. R. Thierry, F. Mouliere, E. Messaoudi, S. Mollevi, C. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, issue.4, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, issue.7404, pp.532-538, 2012.

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci, vol.102, issue.45, pp.16368-73, 2005.

V. Taly, D. Pekin, A. E. Abed, and P. Laurent-puig, Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, issue.7, pp.405-421, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02299585

P. Laurent-puig, D. Pekin, C. Normand, S. K. Kotsopoulos, P. Nizard et al., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, issue.5, pp.1087-97, 2015.

A. Didelot, S. K. Kotsopoulos, A. Lupo, D. Pekin, X. Li et al., Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, issue.5, pp.815-838, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299583

A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. Eclov et al., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, issue.5, pp.548-54, 2014.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, issue.8, pp.1715-1737, 2015.

E. Kidess, K. Heirich, M. Wiggin, V. Vysotskaia, B. C. Visser et al., Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform, Oncotarget, vol.6, issue.4, pp.2549-61, 2015.

N. Pécuchet, Y. Rozenholc, E. Zonta, D. Pietraz, A. Didelot et al., Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA, Clin Chem, vol.62, issue.11, pp.1492-503, 2016.

S. Garrigou, G. Perkins, F. Garlan, C. Normand, A. Didelot et al., A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin Chem, vol.62, issue.8, pp.1129-1168, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02295782

E. Van-cutsem, C. Köhne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, vol.360, issue.14, pp.1408-1425, 2009.

J. Douillard, K. S. Oliner, S. Siena, J. Tabernero, R. Burkes et al., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, vol.369, issue.11, pp.1023-1057, 2013.

E. Van-cutsem, C. Köhne, I. Láng, G. Folprecht, M. P. Nowacki et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, vol.29, issue.15, pp.2011-2020, 2011.

J. Taieb, A. Zaanan, K. L. Malicot, C. Julié, H. Blons et al., Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, vol.2, issue.5, pp.643-53, 2016.

J. Taieb, L. Malicot, K. Shi, Q. Penault-llorca, F. Bouché et al., Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, JNCI J Natl Cancer Inst, vol.109, issue.5, 2017.

M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, issue.10, pp.883-92, 2012.

M. Kleppe and R. L. Levine, Tumor heterogeneity confounds and illuminates: assessing the implications, Nat Med, vol.20, issue.4, pp.342-346, 2014.

K. Spindler, N. Pallisgaard, I. Vogelius, and A. Jakobsen, Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan, Clin Cancer Res, vol.18, issue.4, pp.1177-85, 2012.

J. B. Bachet, Meeting Library | RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study

K. Spindler, N. Pallisgaard, A. L. Appelt, R. F. Andersen, J. V. Schou et al., Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy, Eur J Cancer, vol.51, issue.17, pp.2678-85, 2015.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014.

A. R. Thierry, S. El-messaoudi, C. Mollevi, J. L. Raoul, R. Guimbaud et al., Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment, Ann Oncol, vol.28, issue.9, pp.2149-59, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01682168

T. André, A. De-gramont, D. Vernerey, B. Chibaudel, F. Bonnetain et al., Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study, J Clin Oncol, vol.33, issue.35, pp.4176-87, 2015.

H. Schmoll, J. Tabernero, J. Maroun, F. De-braud, T. Price et al., Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial, J Clin Oncol, vol.33, issue.32, pp.3733-3773, 2015.

F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman et al., Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, issue.9, pp.985-90, 2008.

B. M. Ryan, F. Lefort, R. Mcmanus, J. Daly, P. Keeling et al., A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up, Gut, vol.52, issue.1, pp.101-109, 2003.

J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer et al., Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med, vol.8, issue.346, pp.346-92, 2016.

J. Tie, Meeting Library | The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC)

M. J. Overman, Meeting Library | Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence

F. Garlan, P. Laurent-puig, D. Sefrioui, N. Siauve, A. Didelot et al., Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study), Clin Cancer Res, vol.23, issue.18, pp.5416-5441, 2017.

F. Perrone, A. Lampis, C. Bertan, P. Verderio, C. M. Ciniselli et al., Circulating free DNA in a screening program for early colorectal cancer detection, Tumori J, vol.100, issue.2, pp.115-136, 2014.

L. A. Diaz, R. T. Williams, J. Wu, I. Kinde, J. R. Hecht et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, issue.7404, pp.537-577, 2012.

K. Spindler, N. Pallisgaard, R. F. Andersen, and A. Jakobsen, Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma, Int J Cancer, vol.135, issue.9, pp.2215-2237, 2014.

G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, vol.21, issue.7, pp.795-801, 2015.

S. Mohan, E. Heitzer, P. Ulz, I. Lafer, S. Lax et al., Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing, PLOS Genet, vol.10, issue.3, p.1004271, 2014.

E. Valtorta, S. Misale, A. Sartore-bianchi, I. D. Nagtegaal, F. Paraf et al., KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy, Int J Cancer, vol.133, issue.5, pp.1259-65, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00872285

A. Bardelli, S. Corso, A. Bertotti, S. Hobor, E. Valtorta et al., Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, Cancer Discov, vol.3, issue.6, pp.658-73, 2013.

A. Wong, J. Lim, A. Sinha, A. Gopinathan, R. Lim et al., Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib, J Transl Med, vol.13, issue.1, p.57, 2015.